Shots:

• SyntheX to receive an up front & investment and is eligible for ~$550M in performance-based milestones along with royalties. The collaboration focuses to discover molecular glue degraders
• The collaboration will use SyntheX's ToRNeDO molecular glue discovery platform with BMS's clinical development expertise to discover and develop targeted protein degradation (TPD) therapies
• SyntheX has created proprietary platforms that make use of synthetic biology to build cutting-edge drug discovery engines. In contrast to in vitro screening, SyntheX's platform technologies use genetic engineering to find functional molecular glues using a pre-specified E3 ligase and a neosubstrate of interest

Ref: PRNewswire | Image: BMS